Ligand Pharmaceuticals | LGND - Cost Of Sales


Ligand Pharmaceuticals reported $11.9M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Agenus USD 642K 399K Sep/2025
Amgen USD 1.79B 128M Dec/2025
Anika Therapeutics USD 11.44M 797K Dec/2025
Baxter International USD 2.4B 512M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Enviri Corporation USD 472M 17.65M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
Heron Therapeutics USD 11.12M 795K Dec/2025
Insmed USD 46.16M 15.25M Dec/2025
Intrexon USD 1.01M 344K Jun/2024
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
Karyopharm Therapeutics USD 37.43M 2.41M Sep/2024
Ligand Pharmaceuticals USD 11.9M 733K Sep/2025
MacroGenics USD 10.12M 34.18M Dec/2025
Merck USD 3.32B 531M Dec/2025
Pacira USD 54.62M 6.02M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Veracyte USD 39.28M 1.93M Dec/2025